Cov-hep study: heparin in standard anticoagulation based on citrate for continuous veno-venous hemodialysis in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
Paulo Ricardo Gessolo LinsClaudia Coimbra César de AlbuquerqueCamila Fernandes AssisBruna Cristine Duarte RodriguesBeatriz Pinto E Siqueira CamposEduardo de Oliveira ValleCarla Paulina Sandoval CabreraJeison de Oliveira GoisGabriela Cardoso SeguraFernando Louzada StrufaldiLorena Catelan MainardesRayra Gomes RibeiroDaniela Del Pilar Via Reque CortesLuciana Gil LutfMárcia Fernanda Arantes de OliveiraGabriel Teixeira Montezuma SalesIgor SmolentzovBernardo Vergara ReichertLucia AndradeVictor Faria SeabraCamila Eleuterio RodriguesPublished in: Trials (2020)
No blinding - Open label format NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): Total number of patients 90 (45 per group) TRIAL STATUS: Trial version 2.0 - ongoing recruitment. First recruitment: June 29, 2020 Estimated date for last recruitment: December 31, 2020 TRIAL REGISTRATION: Responsible Party: University of Sao Paulo General Hospital (Hospital das Clinicas) ClinicalTrials.gov Identifier: NCT04487990 , registered July 27, 2020, ReBec www.ensaiosclinicos.gov.br/rg/RBR-45kf9p/ Other Study ID Numbers: U1111-1252-0194 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1) In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Keyphrases
- phase iii
- open label
- phase ii
- study protocol
- end stage renal disease
- clinical trial
- randomized controlled trial
- chronic kidney disease
- healthcare
- venous thromboembolism
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- sars cov
- double blind
- extracorporeal membrane oxygenation
- prognostic factors
- atrial fibrillation
- rheumatoid arthritis
- emergency department
- placebo controlled
- respiratory syndrome coronavirus
- phase ii study